NEW POTENTIALS FOR THE USE OF SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the latest data on the status of the problem of the treatment of neuroendocrine tumors (NETs) with somatostatin analogues. The results of the international randomized PROMID and CLARINET trials are discussed. PROMID trial, conducted in 18 centers in Germany and included 85 patients, has showed the antiproliferative effect of octreotide depo (Sandostatin LAR) in low-grade (Gr1) NETs of the gastrointestinal tract, 40% of which were functioning and 60% - non-functioning, with a statistically significant increase in progression-free survival. The CLARINET multicenter study conducted in 14 countries, 204 patients were randomized, compared the treatment of lanreotide (Somatulin® Autozhel®) and placebo. All patients had non-functioning NETs of pancreas and gastrointestinal tract; according to degree of differentiation, G1 was diagnosed in 70 %, and G2 <10% - in 30% of patients. In this group of patients, antiproliferative activity of lanreotide was confirmed at a dose of 120 mg, appointed once a 28 days, with a reduction in risk of progression by 53% and achievement of median progression-free survival of 32.8 months in patients receiving lanreotide initially, and in patients in the placebo group translated to lanreotide treatment after 24 months of observation (the result was obtained in the extended investigation CLARINET).

Full Text

Restricted Access

About the authors

V. A Gorbunova

FSBI «RORC n.a. N.N. Blokhin» of RMH

Email: veragorbounova@mail.ru
MD, Prof., Head of the Department of Chemotherapy Moscow

References

  1. Oberndorfer S. Ueber die «kleinen Dünndarmcarcinoma». Verh. Dtsch. Pathol. 1907;11:113-16.
  2. Perren A., Anlauf M., Komminoth P. Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Arch. 2007;451(Suppl 1):539-46.
  3. Resbi J.C., Waser B. Concominant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multi-receptor tumor targeting. Eur. J. Nucl. Med. 2003;30:781-93.
  4. Plockinger U, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl 1):571-80.
  5. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994;5:503-19.
  6. Arnold R., Benning R., Neuhaus C., Rolwage M., Trautmann M.E. Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. The German Sandostatin Study Group. Digestion. 1993;54(Suppl 1):72-5.
  7. Panzuto F., Di Fonzo M., Jannicelli E., Sciuto R., Maini C.L., Capurso G., Milione M., Cattaruzza M.S., Falconi M., David V., Ziparo V., Pederzoli P., Bordi C., Delle Fave G. Long-term clinical outcome of Somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann. Oncol. 2006;17:461-66.
  8. Aparicio T., Ducreux M., Baudin E., Sabourin J.C., Mitry E., Schlumberger M., Rougier P. Antitumor activities of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer. 2001;37:1014-19.
  9. DiBartolomeoM.,BajettaE.,BuzzoniR.,MarianiL., Carnaghi C., Somma L., Zilembo N., Di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
  10. Arnold R., Neuhaus C., Benning R., Schwerk W.B., Trautmann M.E., Joseph K., Bruns C. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic gastroenteropancreatic tumors. World J. Surg. 1993;17: 511-19.
  11. Yao J.C., Hassan M.M., Phan A., et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J. Clin. Oncol. 2008;26:3063-70.
  12. Arnold R., Müller H., Schade-Brittinger C., Rinke A., Klose K., Barth P., Wied M., Mayer C., Aminossadati B.; PROMID Study Group. Germany Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J. Clin. Oncol.2009;27:15(suppl): abstr 4508.
  13. Rinke A., Müller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 2009;27(28):4656-63.
  14. Caplin M.E., Pavel M., Cwikla J.B., Phan A.T., Raderer M., Sedlackova E., Cadiot G., Wolin E.M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Blumberg J., Ruszniewski P.; CLARINET Investigators. Lanreotide in metastatic Enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 2014;371(3):224-33.
  15. Caplin M.E., et al. North American Neuroendocrine Tumor Symposium, Charleston, South Carolina, USA, 2013 (poster).
  16. Caplin M.E., Ruszniewski P.B., Pavel M.E., et al. Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study. J. Clin. Oncol. 2014;32:281(suppl 15s): abstr 4107.
  17. Caplin M., Ruszniewski P., Pavel M., et al. Lanreotide Autogel/Depot shows antitumor effects in patients with metastatic enteropan-creatic NETs: results of the CLARINET extension study. Endocrine Rev. 2014;35(suppl):abstr MON-0320.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies